The landscape of oncology is undergoing a seismic shift. For decades, a diagnosis of metastatic breast cancer...
Patient Advocacy and Support
By Douglas Feil, NBCF Chief Program Officer In recent years, Glucagon-like peptide-1 (GLP-1) receptor agonists have surged...
Introduction: A Growing Concern Amidst Medical Advancements In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized...
NEW YORK, NY — As the world enters the mid-point of Breast Cancer Awareness Month, a global...
The landscape of HER2-positive metastatic breast cancer (mBC) treatment has reached a significant milestone with the recent...
TORONTO, ON – As the medical community continues to make strides in early detection and acute treatment...
By Douglas Feil, Chief Program Officer, National Breast Cancer Foundation (NBCF) In recent years, glucagon-like peptide-1 (GLP-1)...
NEW YORK, NY — As the sun sets on October 13, 2026, the global skyline will undergo...
The landscape of HER2-positive metastatic breast cancer (MBC) treatment has reached a significant milestone. The U.S. Food...
TORONTO — As the landscape of oncology shifts from a singular focus on acute treatment toward a...
